Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
View Patent ↗A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi , anaerobic microorganisms such as Bacteroides and Clostridia , and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium . Accordingly, the compositions comprising the crystalline form may be used in antibiotics.
1. Crystalline particles comprising
at least about 96% by weight of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate, characterized by x-ray powder pattern diffraction data comprising peaks at 14.7°, 15.2°, 16.6°, 20.3°, 26.8° and 28.2°,
wherein the remainder of the crystalline particles comprises at least one compound selected from the group consisting of:
2. The crystalline particles of claim 1 , wherein the remainder of the crystalline particles further comprises at least one compound selected from the group consisting of:
3. The crystalline particles of claim 2 , wherein the remainder of the crystalline particles further comprises the compound:
4. The crystalline particles of claim 3 , wherein the remainder of the crystalline particles further comprises at least one compound selected from the group consisting of:
5. The crystalline particles of claim 4 , wherein the remainder of the crystalline particles further comprises the compound:
6. The crystalline particles of claim 1 , wherein the median volume diameter is at least about 1.0 μm.
7. A pharmaceutical composition comprising the crystalline particles of claim 1 and at least one pharmaceutically acceptable carrier, excipient, or diluent.
8. A reaction mixture comprising the crystalline particles of claim 1 and a base.
9. The reaction mixture of claim 8 , wherein the base is sodium hydroxide.
10. A pharmaceutical composition comprising a lyophilisate of the reaction mixture of claim 8 , the pharmaceutical composition comprising:
wherein R═PO(ONa) 2 ;
at least one compound selected from the group consisting of:
and at least one pharmaceutically acceptable carrier, excipient, or diluent.
11. The pharmaceutical composition of claim 10 , further comprising at least one compound selected from the group consisting of:
12. The pharmaceutical composition of claim 11 , further comprising the compound:
13. A method of treating a bacterial infection comprising administering an effective amount of the pharmaceutical composition of claim 7 to a subject in need thereof.
14. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is in the form of an oral dosage form.
15. A lyophilized powder for injection made by a process comprising mixing a compound of formula
wherein R═PO(OH) 2 , with a sodium hydroxide solution to form a disodium salt of said compound and then lyophilizing the resulting solution.
16. A method of treating a bacterial infection comprising administering an effective amount of the lyophilized powder of claim 15 to a subject in need thereof.
17. The method of claim 16 , wherein the bacterial infection results from a Gram-positive bacterium.
18. The method of claim 17 , wherein the Gram-positive bacterium is selected from the group consisting of methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci (VRE).
19. The method of claim 13 , wherein the bacterial infection results from a Gram-positive bacterium.
20. The method of claim 19 , wherein the Gram-positive bacterium is selected from the group consisting of methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci (VRE).
21. The method of claim 19 , wherein from about 1 mg to about 500 mg of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate is administered.
22. The method of claim 21 , wherein from about 5 mg to about 200 mg of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate is administered.
23. The method of claim 21 , wherein about 200 mg of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate is administered.
24. A pharmaceutical composition that comprises crystalline particles according to claim 1 made by a process comprising contacting a salt of (R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate with an acid solution.
25. The pharmaceutical composition of claim 24 , wherein the acid solution comprises (a) HCl and ethanol, or (b) HCl and tetrahydrofuran.
26. The pharmaceutical composition of claim 24 , wherein the process by which the crystalline particles of the pharmaceutical composition are made further comprises filtering the crystalline particles from a supernatant.
27. The pharmaceutical composition of claim 26 , wherein the process by which the crystalline particles of the pharmaceutical composition are made further comprises drying the crystalline particles.